We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05341609
Recruitment Status : Completed
First Posted : April 22, 2022
Last Update Posted : September 21, 2022
Sponsor:
Information provided by (Responsible Party):
Vigonvita Life Sciences

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) Compared With Paxlovid for the Treatment of Coronavirus Disease 2019 (COVID-19) in Participants With Mild to Moderate COVID-19.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: JT001 Drug: Paxlovid Phase 3

Detailed Description:

Screening Interested participants will sign the appropriate informed consent form (ICF) prior to completion of any study procedures.

The investigator will review symptoms, risk factors and other non-invasive inclusion and exclusion criteria prior to any invasive procedures.

Treatment and Assessment Period

This is the general sequence of events during the 28-day treatment and assessment period:

Complete baseline procedures Participants are randomized to an intervention group Participants receive study intervention (Q12H X 5 days), and Complete all safety monitoring

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 822 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Single-blind, Randomized, Controlled Study to Evaluate the Efficacy and Safety of JT001 (VV116) Compared With Paxlovid for the Early Treatment of COVID-19 in Participants With Mild to Moderate COVID-19
Actual Study Start Date : April 4, 2022
Actual Primary Completion Date : May 13, 2022
Actual Study Completion Date : May 31, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Ritonavir

Arm Intervention/treatment
Experimental: JT001(VV116)
Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
Drug: JT001
Day 1: 600mg, Q12H X 1 day; Day 2~5: 300mg, Q12H X 4 days
Other Name: VV116

Active Comparator: Paxlovid
Day 1~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
Drug: Paxlovid
Day 1~5: 300 mg of Nirmatrelvir and 100 mg of ritonavir, Q12H X 5 days
Other Name: Nirmatrelvir / ritonavir




Primary Outcome Measures :
  1. Time to sustained clinical recovery [ Time Frame: Up to 28 days ]
    Time to sustained clinical recovery up to 28 days.


Secondary Outcome Measures :
  1. AEs and SAEs through Day 28 [ Time Frame: Up to 28 days ]
    AEs and SAEs through Day 28

  2. Percentage of participants who experience these events by Day 28 [ Time Frame: Day 1 to 28 days ]

    Percentage of participants who experience these events by Day 28

    Progress to severe and/or critical COVID-19; Death from any cause


  3. Percentage of clinical recovery participants [ Time Frame: Days 3, 5, 7, 10, 14, 21 and 28 ]
    Percentage of clinical recovery participants from baseline to Days 3, 5, 7, 10, 14, 21 and 28

  4. The change of COVID-19 symptom scores [ Time Frame: Days 3, 5, 7, 10, 14, 21 and 28 ]
    The change of "COVID-19 symptom scores" from baseline to Days 3, 5, 7, 10, 14, 21 and 28, the score ranges from 0 to 33 and higher scores mean a worse symptom.

  5. The change of WHO clinical progression scale [ Time Frame: Days 3, 5, 7, 10, 14, 21 and 28 ]
    The change of "WHO clinical progression scale" from baseline to Days 3, 5, 7, 10, 14, 21 and 28, the score ranges from 0 to 10 and higher scores mean a worse clinical progression.

  6. Percentage of participants with SARS-CoV-2 clearance [ Time Frame: Days 3, 5, 7, 10, 14 ]
    Percentage of participants with SARS-CoV-2 clearance on Days 3, 5, 7, 10 and 14

  7. The change of SARS-COV-2 Ct value [ Time Frame: Days 3, 5, 7, 10, 14 ]
    The change of SARS-COV-2 Ct value at Days 3, 5, 7, 10, 14

  8. The change of Chest CT scan [ Time Frame: Days 7 or 10 ]
    The change of Chest CT scan from baseline to Days 7 or 10. The change from baseline involves not changed, getting worse, getting better as assessed by the investigator.

  9. Percentage of the participants who have progression of COVID-19 though Day 28 [ Time Frame: Up to 28 days ]
    Progress to severe and/or critical COVID-19; Death from any cause

  10. Percentage of participants whose "WHO clinical progression scale" reduced at least one level [ Time Frame: Days 3, 5, 7, 10, 14, 21 and 28 ]
    Percentage of participants whose "WHO clinical progression scale" reduced at least one level from baseline to Days 3, 5, 7, 10, 14, 21 and 28. The score ranges from 0 to 10 and the higher scores mean a worse clinical progression level.

  11. Time to sustained clinical symptom resolution [ Time Frame: Up to 28 days ]
    Time to sustained clinical symptom resolution

  12. Percentage of participants with clinical symptom resolution [ Time Frame: Days 3, 5, 7, 10, 14, 21 and 28 ]
    Percentage of participants with clinical symptom resolution from baseline to Days 3, 5, 7, 10, 14, 21 and 28



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants who have a positive SARS-CoV-2 test result.
  • Participants who have one or more mild or moderate COVID-19 symptoms, and total symptom score ≥ 2.
  • Participants who have one or more of the following requirements: ≤7 days from the first positive test for SARS-COV-2 virus infection to the first dose; ≤5 days from the first onset of COVID-19 symptoms to the first dose; SARS-CoV-2 Ct Value ≤20 within 24 hours prior to the first dose.
  • Participants who satisfy one or more than one of the following high risks for progression to severe COVID-19, including death.
  • Participants who must agree to adhere to contraception restrictions.
  • Participants who understand and agree to comply with planned study procedures.
  • Participants or legally authorized representatives can give written informed consent approved by the Ethical Review Board governing the site.
  • Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

  • Participants who are judged by the investigator as likely to progress to severe/critical COVID-19 prior to randomization.
  • Participants who have SpO2≤93% on room air at sea level or PaO2/FiO2≤ 300, or respiratory rate ≥30 per minute.
  • Participants who require mechanical ventilation or anticipated impending need for mechanical ventilation.
  • Participants who have eye disease.
  • Participants who have any of the following conditions when screening: ALT or AST>1.5 ULN; e GFR <60 mL/min.
  • Participants who have known allergies to any of the components used in the formulation of the interventions.
  • Any medical condition, which in the opinion of the Investigator, will compromise the safety of the participant.
  • Participants who have received a SARS-CoV-2 monoclonal antibody treatment or prevention, or antiviral treatment (including the investigational treatment).
  • Participants who have received convalescent COVID-19 plasma treatment.
  • Participant's use of contraindicated drugs in the Package Insert of Nirmatrelvir Tablet/Ritonavir Tablets.
  • Participants who have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed.
  • Participants who are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Female who is pregnant or breast-feeding or plan to be pregnant within this study period.
  • Male whose wife or partner plan to be pregnant within this study period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05341609


Locations
Layout table for location information
China, Shanghai
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai, China, 200020
Shanghai Tongren Hospital
Shanghai, Shanghai, China, 200050
Shanghai Public Health Clinical Center
Shanghai, Shanghai, China, 200093
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai, China, 200127
ShuGuang Hospital
Shanghai, Shanghai, China, 201203
Shanghai Pudong Hospital
Shanghai, Shanghai, China, 201399
Huashan Hospital affiliated to Fudan University
Shanghai, Shanghai, China, 201900
Sponsors and Collaborators
Vigonvita Life Sciences
Investigators
Layout table for investigator information
Principal Investigator: Guang Ning Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Layout table for additonal information
Responsible Party: Vigonvita Life Sciences
ClinicalTrials.gov Identifier: NCT05341609    
Other Study ID Numbers: JT001-010-COVID-19
First Posted: April 22, 2022    Key Record Dates
Last Update Posted: September 21, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Vigonvita Life Sciences:
JT001(VV116)
Mild to Moderate COVID-19
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Ritonavir
HIV Protease Inhibitors
Viral Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors